Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

This study is an open-label, multicenter Phase II trial, planning to enroll 200 subjects, using BEBT-109 capsules as monotherapy, aimed at evaluating the efficacy and safety of BEBT-109 capsules in subjects with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in locally advanced or metastatic Non-Small Cell Lung Cancer （NSCLC）.

Trial Details

NCT ID

NCT06706713

Phase

PHASE2

Sponsor

BeBetter Med Inc

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

BEBT-109 Capsule

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25
Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Subjects who have been fully informed and are willing to sign the informed consent form.
Age of at least 18 years, with no gender restrictions.
According to the 8th edition of the American Joint Committee on Cancer (AJCC) lung cancer Tumor Node Metastasis (TNM) staging criteria: histologica…
Written test reports confirm the occurrence of EGFR exon 20 insertion mutations.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →